Research programme: stroke therapies - AGY Therapeutics
Latest Information Update: 10 Oct 2006
Price :
$50 *
At a glance
- Originator AGY Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 10 Oct 2006 Discontinued - Preclinical for Stroke in USA (PO)
- 02 Sep 2002 Preclinical trials in stroke in USA (PO)